BET inhibitors: a novel epigenetic approach

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Oncology

• Publication date

  2017-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/annonc/mdx157PMID 28838216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

  2017cited by this paper
• PROTAC BET degraders are more broadly effective than BET inhibitors

  2016cited by this paper
• Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.

  2016cited by this paper
• BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

  2016cited by this paper
• BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells

  2016cited by this paper
• Abstract 4702: Combination of BET inhibitor INCB054329 and LSD1 inhibitor INCB059872 is synergistic for the treatment of AMLin vitroandin vivo

  2016cited by this paper
• BRD4 is a Histone Acetyltransferase that Evicts Nucleosomes from Chromatin

  2016cited by this paper
• Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

  2016cited by this paper
• Abstract 4904: The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models

  2016cited by this paper
• Abstract 2473: Combined BET-bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

  2016cited by this paper
• The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo

  2016cited by this paper
• BET bromodomain inhibition synergizes with immune checkpoint blockade to facilitate anti-tumor response in a murine model of non-small cell lung cancer harboring activating KRAS mutation

  2016cited by this paper
• A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

  2016cited by this paper
• Abstract 3780: Activity of the BET inhibitor INCB054329 in models of lymphoma

  2016cited by this paper
• Epigenetics: A primer for clinicians.

  2016cited by this paper
• Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

  2016cited by this paper
• Abstract LB-207: Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC)

  2016cited by this paper
• Combination of the novel BET inhibitor BI 894999 with CDK9 inhibition suggests a promising regimen for the treatment of AML

  2016cited by this paper
• Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

  2016cited by this paper
• The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects

  2016cited by this paper
• Abstract 4738: The BET family bromodomain inhibitor ABBV-075 is a promising therapeutic agent for acute myeloid leukemia and myelodysplastic syndrome

  2016cited by this paper
• Abstract 4700: BET bromodomain inhibition is a promising treatment strategy for distinct subsets of lethal castration-resistant prostate cancer

  2016cited by this paper
• Mechanisms of tumor cell resistance to the current targeted-therapy agents

  2016cited by this paper
• Clinical progress and pharmacology of small molecule bromodomain inhibitors.

  2016cited by this paper
• BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma

  2016cited by this paper
• First-in-human phase I dose escalation study of the Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects with advanced malignancies

  2016cited by this paper
• Molecular Pathways: Targeting the PI3K Pathway in Cancer—BET Inhibitors to the Rescue

  2016cited by this paper
• Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells

  2015cited by this paper
• Targeting the histone orthography of cancer: drugs for writers, erasers and readers

  2015cited by this paper
• Histone deacetylase inhibitors in hematological malignancies and solid tumors

  2015cited by this paper
• Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma

  2015cited by this paper
• Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors

  2015cited by this paper
• BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

  2015cited by this paper
• BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

  2015cited by this paper
• Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

  2015cited by this paper
• Concomitant BET and MAPK blockade for effective treatment of ovarian cancer

  2015cited by this paper
• Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

  2015cited by this paper
• The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

  2015cited by this paper
• Overcoming Resistance to Targeted Therapies in Cancer.

  2015cited by this paper
• The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

  2014cited by this paper
• Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

  2014cited by this paper
• Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

  2014cited by this paper
• A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

  2014cited by this paper
• An epigenomic approach to therapy for tamoxifen-resistant breast cancer

  2014cited by this paper
• Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

  2014cited by this paper
• BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

  2014cited by this paper
• Targeting bromodomains: epigenetic readers of lysine acetylation

  2014cited by this paper
• The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

  2014cited by this paper
• What are super-enhancers?

  2014cited by this paper
• PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.

  2013cited by this paper
• Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

  2013cited by this paper
• BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.

  2013cited by this paper
• BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

  2013cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013cited by this paper
• Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

  2013cited by this paper
• Master transcription factors and mediator establish super-enhancers at key cell identity genes.

  2013cited by this paper
• Two faces of BRD4

  2013cited by this paper
• Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

  2013cited by this paper
• BET domain co-regulators in obesity, inflammation and cancer

  2012cited by this paper
• First drugs found to inhibit elusive cancer target

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3

  2011cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011cited by this paper
• Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

  2010cited by this paper
• Suppression of inflammation by a synthetic histone mimic

  2010cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Regulation of Aurora B Expression by the Bromodomain Protein Brd4

  2009cited by this paper
• Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription.

  2009cited by this paper
• Epigenetic changes in cancer.

  2009cited by this paper
• An operational definition of epigenetics.

  2009cited by this paper
• The Bromodomain Protein Brd4 Stimulates G1 Gene Transcription and Promotes Progression to S Phase*

  2008cited by this paper
• Reflecting on 25 years with MYC

  2008cited by this paper
• Epigenetics in cancer.

  2008cited by this paper
• The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription.

  2008cited by this paper
• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

  2007cited by this paper
• Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression

  2007cited by this paper
• Cancer epigenomics: DNA methylomes and histone-modification maps

  2007cited by this paper
• Perceptions of epigenetics

  2007cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• The Myc oncoprotein as a therapeutic target for human cancer.

  2006cited by this paper
• Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.

  2005cited by this paper
• Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A.

  2005cited by this paper
• Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4.

  2005cited by this paper
• Brd4 is required for recovery from antimicrotubule drug-induced mitotic arrest: preservation of acetylated chromatin.

  2005cited by this paper
• The history of cancer epigenetics

  2004cited by this paper
• The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis

  2003cited by this paper
• BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

  2003cited by this paper
• Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

  2002cited by this paper
• Translating the Histone Code

  2001cited by this paper
• RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F.

  2000cited by this paper
• Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways.

  1998cited by this paper
• Chromatin Modifications and Their Function

  year unknowncited by this paper

• The Future of Epigenetics: Emerging Technologies and Clinical Applications

  2026cites this paper
• The research landscape and future of targeting super-enhancers for cancer therapy: a bibliometric analysis

  2026cites this paper
• Epigenetic Regulation of Higher-Order Chromatin Structure (HOCS) and Its Implication in Human Diseases

  2026cites this paper
• Cancer-Associated Fibroblasts in Prostate Cancer: Unraveling Mechanisms and Therapeutic Implications

  2026cites this paper
• KB-0118, A novel BET bromodomain inhibitor, suppresses Th17-mediated inflammation in inflammatory bowel disease.

  2025cites this paper
• Niche-specific epigenetic interventions in the spatially heterogeneous glioblastoma microenvironmental landscape: strategies for radiotherapy enhancement

  2025cites this paper
• The BET degrader BETd-246 demonstrated significant anti-tumor efficacy in T-cell acute lymphoblastic leukemia by inhibiting TRAT1.

  2025cites this paper
• Targeted Protein Acetylation Through Chemically Induced Proximity.

  2025cites this paper
• Use of DNA methylation patterns for early detection and management of lung cancer: Are we there yet?

  2025cites this paper
• Epigenetically modulating macrophage subpopulations to promote long-term allograft survival in a mouse heart transplant model.

  2025cites this paper
• MYCN as an oncogene in pediatric brain tumors

  2025cites this paper
• Cardiometabolic disease management: influences from epigenetics.

  2025cites this paper
• Epigenetic Mechanisms in the Transfer of Metabolic Disorders: A Comprehensive Review

  2025cites this paper
• NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studies

  2025cites this paper
• Loop Plasticity Drives Paralog-Specific Recognition in BET ET Domains

  2025cites this paper
• Double minutes: exploring the formation and oncogenic roles in cancer progression

  2025cites this paper
• Pharmacoinformatic discovery of plant-derived BRD4 inhibitors as potential therapeutic agents for leukemia.

  2025cites this paper
• Hybrid AI/physics pipeline for miniprotein binder prioritization: application to the BRD3 ET domain

  2025cites this paper
• The epigenetic landscape of rheumatoid arthritis: Pathogenesis and drug therapeutic potentials

  2025cites this paper
• Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies

  2025cites this paper
• Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains.

  2025cites this paper
• Bromodomain and extraterminal protein inhibitor JQ1 induces maturation arrest and disrupts the cytoplasmic organization in mouse oocytes under in vitro conditions

  2025cites this paper
• Unlocking the Mysteries of Breast Cancer

  2025cites this paper
• Deep learning model enables the discovery of a novel BET inhibitor YD-851.

  2025cites this paper
• Beyond small molecules: advancing MYC-targeted cancer therapies through protein engineering

  2025cites this paper
• Genetic, epigenetic, and molecular determinants of multiple myeloma and precursor plasma cell disorders: a pathophysiological overview

  2025cites this paper
• Jq1 Induces Apoptosis of Ovarian and Endometrial Endometrioid Carcinoma Cells by Downregulating C-Myc Sex

  2025cites this paper
• Chromatin remodeling complexes: architects influencing breast cancer progression

  2025cites this paper
• The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active

  2025cites this paper
• Non-enzymatic protein targeting agents as a promising strategy for cancer treatment

  2025cites this paper
• PROTACS- targeted protein degradation as a path to precision cancer therapeutics.

  2025cites this paper
• Multidimensional analyses identify genes of high priority for pancreatic cancer research

  2025cites this paper
• Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications

  2025cites this paper
• Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies.

  2025cites this paper
• Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy.

  2025cites this paper
• The Chromatin Remodeler Chd8 Regulates Hematopoietic Stem and Progenitor Cell Survival and Differentiation During Zebrafish Embryogenesis

  2025cites this paper
• Epigenetics modulation of drug resistance pathways in advanced lung cancer.

  2025cites this paper
• TLR4 Inhibition Attenuate Facilitatory Effects of JQ1 on Learning & Memory Via Polarization of Microglia, and BDNF Expression in Alzheimer's Disease Model.

  2025cites this paper
• Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology

  2025cites this paper
• NUT-midline carcinoma of the lung with rare BRD3-NUTM1 fusion

  2024cites this paper
• BRD2‐specific inhibitor, BBC0403, inhibits the progression of osteoarthritis pathogenesis in osteoarthritis‐induced C57BL/6 male mice

  2024cites this paper
• Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines.

  2024cites this paper
• MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch

  2024cites this paper
• Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)

  2024cites this paper
• Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells.

  2024cites this paper
• BET degrader exhibits lower antiproliferative activity than its inhibitor via EGR1 recruiting septins to promote E2F1-3 transcription in triple-negative breast cancer.

  2024cites this paper
• Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein–Ligand Interactions and High Selectivity

  2024cites this paper
• The effects of chitosan-loaded JQ1 nanoparticles on OVCAR-3 cell cycle and apoptosis-related gene expression

  2024cites this paper
• MYC the oncogene from hell: Novel opportunities for cancer therapy.

  2024cites this paper
• Visualization of Modified Bisarylbutadiyne-Tagged Small Molecules in Live-Cell Nuclei by Stimulated Raman Scattering Microscopy.

  2024cites this paper
• The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma.

  2024cites this paper
• Ku70 Targets BRD3-MYC/Cyclin D1 Axis to Drive Hepatocellular Carcinoma Progression.

  2024cites this paper
• BET inhibitor JQ1 induces apoptosis of ovarian and endometrial endometrioid carcinoma cells by downregulating c‑Myc

  2024cites this paper
• Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1

  2024cites this paper
• Epigenetic therapies in cancer treatment: Opportunities and challenges

  2024cites this paper
• Advances in Epigenetic Therapeutics for Breast Cancer.

  2024cites this paper
• Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders.

  2024cites this paper
• The BET inhibitor JQ1 targets fat metabolism and counteracts obesity

  2024cites this paper
• BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3

  2024cites this paper
• Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies

  2024cites this paper
• The role of super-enhancers in head and neck cancer and its potential therapeutic targets.

  2024cites this paper
• Discovery and optimization of novel 4-morpholinothieno[3,2-d]pyrimidine derivatives as potent BET inhibitors for cancer therapy.

  2024cites this paper
• Research progress of BRD4 in head and neck squamous cell carcinoma: Therapeutic application of novel strategies and mechanisms.

  2024cites this paper
• BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1

  2024cites this paper
• Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology

  2024cites this paper
• Liver-targeting chimeras as a potential modality for the treatment of liver diseases.

  2024cites this paper
• An updated patent review of BRD4 degraders

  2024cites this paper
• Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options.

  2024cites this paper
• Histone deacetylase inhibitors for leukemia treatment: current status and future directions

  2024cites this paper
• Pharmacological targeting of the cancer epigenome

  2024cites this paper
• Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis.

  2024cites this paper
• Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)

  2024cites this paper
• Utilizing epigenetic regulators to improve HSC-based lentiviral gene therapy

  2024cites this paper
• Tumor biomarkers for diagnosis, prognosis and targeted therapy

  2024cites this paper
• PROTAC: novel degradable approach for different targets to treat breast cancer.

  2024cites this paper
• Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia

  2024cites this paper
• Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma

  2024cites this paper
• Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors

  2024cites this paper
• Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer

  2024cites this paper
• Chromatin and Cancer: Implications of Disrupted Chromatin Organization in Tumorigenesis and Its Diversification

  2023cites this paper
• Bromodomain-containing Protein 4 Regulates Innate Inflammation in Airway Epithelial Cells via Modulation of Alternative Splicing

  2023cites this paper
• Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors.

  2023cites this paper
• Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer.

  2023cites this paper
• Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy

  2023cites this paper
• Cellular Senescence and Senolytic Agents: Recent Updates on Their Role and Applications.

  2023cites this paper
• High resolution crystal structure of BRD4-BD1 in complex with a novel inhibitor precursor.

  2023cites this paper
• Establishment and characterization of the first patient-derived radiation-induced angiosarcoma xenograft model (RT-AS5)

  2023cites this paper
• A Combination of CPI-0610 and SAHA Induces Apoptosis through STAT3 and p38 Signalling Pathways in Diffuse Large B-cell Lymphoma Cells.

  2023cites this paper
• Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.

  2023cites this paper
• Epigenetic Modulators as Therapeutic Agents in Cancer

  2023cites this paper
• Protein acetylation and related potential therapeutic strategies in kidney disease.

  2023cites this paper
• Regulation of cholesterol metabolism: New players for an old physiological process

  2023cites this paper
• Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer

  2023cites this paper
• Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

  2023cites this paper
• Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.

  2023cites this paper
• ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways

  2023cites this paper
• Novel molecule BBC0901 inhibits BRD4 and acts as a catabolic regulator in the pathogenesis of osteoarthritis.

  2023cites this paper
• BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review.

  2023cites this paper
• A deregulated m6A writer complex axis driven by BRD4 confers an epitranscriptomic vulnerability in combined DNA repair–targeted therapy

  2023cites this paper
• A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy.

  2023cites this paper